Login / Signup

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.

Margitta WormJacob P ThyssenSibylle SchliemannAndrea BauerVivian Y ShiBen EhstSandra TillmannSofie KornKatarina ResenTove Agner
Published in: The British journal of dermatology (2022)
In this trial, delgocitinib cream showed a dose-response relationship in terms of efficacy and was well tolerated.
Keyphrases
  • phase iii
  • phase ii
  • placebo controlled
  • open label
  • clinical trial
  • study protocol
  • double blind
  • drug delivery
  • randomized controlled trial